Cargando…
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts you...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/ https://www.ncbi.nlm.nih.gov/pubmed/37047448 http://dx.doi.org/10.3390/ijms24076473 |
_version_ | 1785023910358548480 |
---|---|
author | Ferraro, Maria Grazia Bocchetti, Marco Riccardi, Claudia Trifuoggi, Marco Paduano, Luigi Montesarchio, Daniela Misso, Gabriella Santamaria, Rita Piccolo, Marialuisa Irace, Carlo |
author_facet | Ferraro, Maria Grazia Bocchetti, Marco Riccardi, Claudia Trifuoggi, Marco Paduano, Luigi Montesarchio, Daniela Misso, Gabriella Santamaria, Rita Piccolo, Marialuisa Irace, Carlo |
author_sort | Ferraro, Maria Grazia |
collection | PubMed |
description | Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC. |
format | Online Article Text |
id | pubmed-10094725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100947252023-04-13 Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem Ferraro, Maria Grazia Bocchetti, Marco Riccardi, Claudia Trifuoggi, Marco Paduano, Luigi Montesarchio, Daniela Misso, Gabriella Santamaria, Rita Piccolo, Marialuisa Irace, Carlo Int J Mol Sci Article Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC. MDPI 2023-03-30 /pmc/articles/PMC10094725/ /pubmed/37047448 http://dx.doi.org/10.3390/ijms24076473 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferraro, Maria Grazia Bocchetti, Marco Riccardi, Claudia Trifuoggi, Marco Paduano, Luigi Montesarchio, Daniela Misso, Gabriella Santamaria, Rita Piccolo, Marialuisa Irace, Carlo Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title | Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title_full | Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title_fullStr | Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title_full_unstemmed | Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title_short | Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem |
title_sort | triple negative breast cancer preclinical therapeutic management by a cationic ruthenium-based nucleolipid nanosystem |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/ https://www.ncbi.nlm.nih.gov/pubmed/37047448 http://dx.doi.org/10.3390/ijms24076473 |
work_keys_str_mv | AT ferraromariagrazia triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT bocchettimarco triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT riccardiclaudia triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT trifuoggimarco triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT paduanoluigi triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT montesarchiodaniela triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT missogabriella triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT santamariarita triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT piccolomarialuisa triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem AT iracecarlo triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem |